Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Part of paid clinical trials in Phoenix, Arizona.

Sponsor
Revolution Medicines, Inc.
Study ID
NCT07491445
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • daraxonrasib — DRUG
    oral tablets
  • gemcitabine — DRUG
    intravenous (IV) infusion
  • nab-paclitaxel — DRUG
    IV infusion

Study Details

The purpose of this study is to evaluate the safety and efficacy of an investigational RAS(ON) inhibitor administered as monotherapy or in combination with chemotherapy, compared with standard of care (SOC) chemotherapy alone.

Key Dates

First listed
Mar 24, 2026
Start date
Mar 9, 2026
Status verified
Sep 2026
Primary completion
Jun 30, 2028
Completion
Mar 31, 2029

Study Design

Enrollment
900 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Arm A: daraxonrasib
    study drug
  • Experimental: Arm B: daraxonrasib + gemcitabine and nab-paclitaxel
    study drug in combination with chemotherapy
  • Active Comparator: Arm C: gemcitabine and nab-paclitaxel
    SOC chemotherapy

Primary Outcome Measure

Progression free survival (PFS) [ Time Frame: Up to approximately 2 years ]

Central Contacts

Locations (20)

FacilityCityStateZIPSite coordinators
Mayo Clinic - ScottsdalePhoenixArizona85054-
Honor Health Research InstituteScottsdaleArizona85258
Carolina Robertson
[email protected]
University of California Los Angeles Health - Hematology/OncologyLos AngelesCalifornia90095
Bindu Cherian
[email protected]
310-205-0771
University of California San FranciscoSan FranciscoCalifornia94158
Kevin Lopez
415-353-7070
Mayo Clinic Cancer Center- FloridaJacksonvilleFlorida32224-
H Lee Moffitt Cancer Center and Research InstituteTampaFlorida33612
Cheyenne Schneider
[email protected]
813-745-3691
Johns Hopkins Sidney Kimmel Comprehensive Cancer CenterBaltimoreMaryland21287
Colleen Apostol
[email protected]
410-614-3644
Dana-Farber Cancer InstituteBostonMassachusetts02215
Danielle Lindquist
[email protected]
857-215-2351
Mayo Clinic Cancer Center- RochesterRochesterMinnesota55905-
Comprehensive Cancer Centers of NevadaHendersonNevada89052-
Memorial Sloan Kettering Cancer CenterNew YorkNew York10065
Wungki Park
[email protected]
646-888-4543
Duke University Medical CenterDurhamNorth Carolina27710
Tia Jones
[email protected]
919-681-3095
University of Cincinnati Cancer CenterCincinnatiOhio45219
Alexis Brenner
[email protected]
513-584-5725
Taylor Cancer Research CenterMaumeeOhio43537-
SCRI Oncology PartnersNashvilleTennessee37203
Karlie Williams
[email protected]
615-329-7274
SCRI - Texas Oncology DallasDallasTexas95246
Christine Terraciano
[email protected]
214-370-1000
MD Anderson Cancer CenterHoustonTexas77030
Kamisha Jernigan
[email protected]
Huntsman Cancer InstituteSalt Lake CityUtah84112-
Virginia Cancer SpecialistsFairfaxVirginia22031
Carrie Friedman
[email protected]
571-350-8400
Virginia Mason Medical CenterSeattleWashington98101
Das Rishika
[email protected]
206-287-6273

Find similar trials in Phoenix, AZ

Nationwide
Pancreatic cancer trialsOncology trialsGI oncology trials
By condition
Pancreatic cancer
By specialty
OncologyGI oncology
By research site
Mayo Clinic - Scottsdale· Phoenix, AZHonor Health Research Institute· Scottsdale, AZUniversity of California Los Angeles Health - Hematology/Oncology· Los Angeles, CAUniversity of California San Francisco· San Francisco, CAMayo Clinic Cancer Center- Florida· Jacksonville, FLH Lee Moffitt Cancer Center and Research Institute· Tampa, FL

Related Studies